Condition
Cognition Disorder
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 12 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
12 shownA Multi-domain Lifestyle Intervention Among Aged Community-residents in Zhejiang, ChinaNCT05886114 · 2023-05-28
RECRUITINGREPAIR Sleep StudyNCT07572565 · 2026-07-01
NOT_YET_RECRUITINGPolyamine Treatment in Elderly Patients With Coronary Artery DiseaseNCT06186102 · 2024-01-01
COMPLETEDThe Role of EEG in Identifying Cognitive Changes in Parkinson's DiseaseNCT06145776 · 2023-08-02
UNKNOWNThe Impact TDCS-linked Motor and Cognitive Training Gains in Parkinson's DiseaseNCT04581590 · 2022-10-03
ACTIVE_NOT_RECRUITINGThe Impact of Aripiprazole Long-acting on Myelin and Cognition in the Onset of SchizophreniaNCT05322031 · 2022-08-01
COMPLETEDStudy to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of ACD856NCT05077501 · 2021-09-29
COMPLETEDThe SINgapore GERiatric Intervention Study to Reduce Cognitive Decline and Physical Frailty (SINGER) StudyNCT05007353 · 2021-08-23
COMPLETEDStudy to Evaluate the Effects of Single Ascending Oral Doses of ACD856 on Safety, Tolerability and PharmacokineticsNCT05077631 · 2021-02-15
COMPLETEDSelf-screening of Cognitive Impairment in Primary CareNCT04019665 · 2020-05-27
WITHDRAWNStudy Evaluating the Pharmacokinetics of a Single Microdose of ACD856NCT05783830 · 2020-01-13
COMPLETEDA Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive ImpairmentNCT00240695 · 2003-05-01
COMPLETEDCommon interventions
ACD856DRUG3PlaceboDRUG2Self-Guided InterventionBEHAVIORAL2ACD856 (fed cohort)DRUG1AripiprazoleDRUG1Cognitite-motor Dual Task Training (DT training)OTHER1Cognitive trainingOTHER1galantamine hydrobromideDRUG1Healthy LivingBEHAVIORAL1MMSE (mini mental state examination)OTHER1PlaceboOTHER1REPAIR SleepBEHAVIORAL1SAGE (Self-Administered Gerocognitive Exam)OTHER1SpermidineDIETARY_SUPPLEMENT1Structured Lifestyle InterventionBEHAVIORAL1Structured Multi-domain InterventionBEHAVIORAL1tDCS + tredmill training (Standart trehab training)OTHER1
Leading sponsors
AlzeCure Pharma
3
Federal University of Paraíba
2
Centre Hospitalier Universitaire, Amiens
1
Emory University
1
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
1
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
1
National University of Singapore
1
University of Aarhus
1
Zhejiang University
1
Trial status mix
COMPLETED7
ACTIVE_NOT_RECRUITING1
NOT_YET_RECRUITING1
RECRUITING1
UNKNOWN1
WITHDRAWN1
Phase mix
NA6
PHASE12
EARLY_PHASE11
PHASE21
PHASE31
PHASE41
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.